Corient Private Wealth
IMRX icon

Corient Private Wealth’s Immuneering IMRX Stock Holding History

Corient Private Wealth’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
+77,090
New +$390K ﹤0.01% 2401
2025
Q4 		– Sell
-36,090
Closed -$253K – 2707
2025
Q3 		$253K Sell
36,090
-27,650
-43% -$143K ﹤0.01% 2222
2025
Q2 		$215K Buy
+63,740
New +$109K ﹤0.01% 2198
2025
Q1 		– Sell
-63,740
Closed -$140 – 2359
2024
Q4 		$140 Hold
63,740
– – ﹤0.01% 2351
2024
Q3 		$159K Buy
63,740
+20,370
+47% +$29.6K ﹤0.01% 2261
2024
Q2 		$55.5K Hold
43,370
– – ﹤0.01% 2252
2024
Q1 		$125K Buy
43,370
+14,000
+48% +$78.4K ﹤0.01% 2161
2023
Q4 		$216K Sell
29,370
-15,284
-34% -$102K ﹤0.01% 2036
2023
Q3 		$343K Hold
44,654
– – ﹤0.01% 1689
2023
Q2 		$453K Sell
44,654
-2,000
-4% -$19.2K ﹤0.01% 1498
2023
Q1 		$453K Sell
46,654
-765
-2% -$4.34K ﹤0.01% 1425
2022
Q4 		$230K Buy
+47,419
New +$420K ﹤0.01% 1441

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Corient Private Wealth's IMRX Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Immuneering (IMRX) in Q2 2026: 77,090 shares worth $385K. The stake represents ﹤0.01% of the portfolio and ranks #2401 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in IMRX as recently as Q3 2025.

Corient Private Wealth first reported a position in IMRX in Q4 2022 and has held it in 12 quarters since. The position peaked at $453K in Q1 2023. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Corient Private Wealth held 77,090 shares of Immuneering worth $385K as of Q2 2026.
  • Immuneering was a new Corient Private Wealth position in Q2 2026.
  • Immuneering made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2401 holding.
  • Corient Private Wealth first reported a position in Immuneering in Q4 2022 and has held it in 12 quarters since.
  • Corient Private Wealth's Immuneering position peaked at $453K in Q1 2023.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.